Company intelligence / Profile preview

Sporos BioDiscovery

Houston, Texas, United Statessporosbiodiscovery.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Sporos BioDiscovery is developing a diversified pipeline of small molecule precision oncology therapeutics. Its lead candidate, SPR1/SPR1‑0117, is a next-generation TEAD inhibitor with isoform selectivity for TEAD1 and TEAD4. Preclinical data show single-agent activity against multiple TEAD-dependent cell lines and synergistic effects in combination with MAPK pathway inhibitors. No clinical results have been reported as all programs are preclinical.

Therapeutic areas: Oncology
Modalities: Small moleculeAntibody-drug conjugate (for parent/portfolio context)
Industry: Biotech

Drug pipeline

3 assets

SPR1

Preclinical

2 more assets in the full pipeline.

Partnerships

none disclosed; operates as part of Sporos Bioventures portfolio

Beyond the preview

Go deeper on Sporos BioDiscovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sporos BioDiscovery.